Arthneeti

Biocon Q1 FY27 Share Price & Earnings Call Analysis

₹351.90+0.34% today
Market cap
₹57,382 Cr
P/E
78.91
ROE
1.40%
PEG
-5.35
Price to sales
3.32
Debt to equity
0.45
52W high / low
₹441 / ₹324
Sales growth (5Y)
18.83%
EBITDA margin
20.42%
Net profit margin
2.20%
Promoter holding
44.68%
Sales (last year)
₹17,321 Cr

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Guidance scorecard · Q1 FY27 call

What Biocon Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

Revenue10–20%MarginsFlatCapexNone plannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth.
  • Generics business showing healthy revenue growth (21% YoY) with new launches like liraglutide contributing; further scale-up expected.
  • Continued new product launches planned annually in biosimilars through the end of the decade to sustain growth.
  • Insulin franchise expansion supported by manufacturing capacity increase with EMA approval, expected to drive global demand.
  • Aflibercept launched in US ophthalmology market with strong growth opportunities anticipated.
  • Focus on calibrated profitable growth rather than just market share to ensure sustainable revenue and margin expansion.

2 more points from Biocon Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Biocon Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

None planned
  • Biocon currently holds a small stake in Bicara.
  • Regarding manufacturing in the USA, Biocon does not plan to increase capital expenditure to establish new facilities or capacities; instead, they focus on partnerships and utilizing existing manufacturing facilities.
  • The Biocon Group is looking at having a local manufacturing footprint where needed, primarily through partnerships rather than building new plants.

2 more points from Biocon Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Biocon Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Ask what Biocon Ltd said on the order book →

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Biocon Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Biocon Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Biocon Ltd announcements

All announcements →

Financials of Biocon Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Biocon Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +3,7743,4233,4623,9543,9173,4333,5903,8214,4173,9424,2964,1734,517
Expenses +2,8172,7412,7453,0513,0042,8122,9053,0703,3393,1933,4603,3403,496
Operating Profit9576817179039136206857521,0787498358341,020
OPM %25%20%21%23%23%18%19%20%24%19%19%20%23%
Other Income +15294134587401,1665853578081-176-28
Interest249233248267227236226223212277272210232
Depreciation364358389414407405420425436455473515513
Profit before tax4971842148083191,1469815648797171-68248
Tax %17%19%19%7%30%25%72%48%6%8%22%-24%20%
Net Profit +414149173753223862278145989133-52199
EPS in Rs2.610.841.055.501.135.49-0.130.212.870.230.631.080.78

Financials of Biocon Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +3,0903,3473,8914,1235,5146,3007,1438,18411,17414,75615,26216,927
Expenses +2,3942,9572,9123,2944,1214,6965,5626,3918,76211,54012,00813,472
Operating Profit6963909808291,3941,6041,5811,7932,4123,2163,2543,455
OPM %23%12%25%20%25%25%22%22%22%22%21%20%
Other Income +15863917322834019926072188531,217-60
Interest929266271655868419974897990
Depreciation2212492773854485527158141,1131,5691,6871,957
Profit before tax6247518506101,2151,1861,0689838971,5251,887448
Tax %15%19%19%26%17%27%21%22%28%15%24%18%
Net Profit +5286096884531,0038718467726431,2981,429369
EPS in Rs4.144.595.103.107.546.246.175.403.858.528.442.38
Dividend Payout %20%18%10%16%7%0%0%9%39%6%6%21%

Financials of Biocon Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital100100100300300600600600600600600810
Reserves3,1713,9344,7384,8815,7986,1067,0277,83217,26719,18321,04433,221
Borrowings +1,1172,4782,3022,2642,4222,7154,4815,14718,01916,27718,36215,434
Other Liabilities +1,9881,9472,2542,5453,6724,9936,3826,76315,85619,69318,53414,185
Total Liabilities6,3758,4589,3949,99012,19214,41418,49020,34251,74255,75358,54063,651
Fixed Assets +1,6301,7483,6263,7004,4715,9716,3646,56929,46830,64431,96338,860
CWIP1,6772,2408391,3031,8992,1962,8004,1107,3177,9938,5084,613
Investments2309021,2536751,0129661,9521,5882,0691,0001,1271,779
Other Assets +2,8393,5693,6764,3124,8115,2817,3748,07412,88816,11716,94118,399
Total Assets6,3758,4589,3949,99012,19214,41418,49020,34251,74255,75358,54063,651

Financials of Biocon Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +2113716406621,1551,2831,1601,1771,8522,9544,0611,994
Cash from Investing Activity +-491-1,138-510-684-703-1,505-3,651-1,662-14,260-1,002-203-2,082
Cash from Financing Activity +1861,068-178-240-2423882,56424213,049-2,333-1,854-924
Net Cash Flow-94300-47-26121016572-243641-3802,004-1,012
Free Cash Flow-627-24632-251-337-546-577-7461291,0461,71882
CFO/OP49%158%86%104%104%101%86%80%86%101%139%65%

Financials of Biocon Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9178839486717792117154131129
Inventory Days132153160161199263304309423368346390
Days Payable125172187224231243246216383467460434
Cash Conversion Cycle985957315391134184157551885
Working Capital Days-19-12246-2-318713-68-63-2
ROCE %12%9%12%8%13%13%10%9%6%6%6%4%

Guidance history

How Biocon Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatNone planned——
Q4 FY26 call →10–20%FlatNone planned——
Q3 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

23out of 100

Momentum score · price trend

23 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−5.8%54%
Last 6 months−2.2%50%
Last 3 months−17.3%23%

The price is 27% below its all-time high of ₹481.95 (24 Dec 2020). Stocks more than 20% below their peak have their score halved, so 46 became 23.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Biocon Ltd: 0.4 × 54 + 0.4 × 50 + 0.2 × 23 = 46, halved to 23 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd